Osteoprotegerin and breast cancer risk by hormone receptor subtype: a nested case-control study in the EPIC cohort

Circulating osteoprotegerin (OPG), a member of the receptor activator of nuclear factor kappa-B (RANK) axis, may influence breast cancer risk via its role as the decoy receptor for both the RANK ligand (RANKL) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Circulating OPG and b...

ver descrição completa

Detalhes bibliográficos
Principais autores:	Fortner, RT, Sarink, D, Schock, H, Johnson, T, Tjønneland, A, Olsen, A, Overvad, K, Affret, A, His, M, Boutron-Ruault, MC, Boeing, H, Trichopoulou, A, Naska, A, Orfanos, P, Palli, D, Sieri, S, Mattiello, A, Tumino, R, Ricceri, F, Bueno-de-Mesquita, HB, Peeters, PH, Van Gils, CH, Weiderpass, E, Lund, E, Quirós, JR, Agudo, A, Sánchez, MJ, Chirlaque, MD, Ardanaz, E, Dorronsoro, M, Key, T, Khaw, KT, Rinaldi, S, Dossus, L, Gunter, M, Merritt, MA, Riboli, E, Kaaks, R
Formato:	Journal article
Idioma:	English
Publicado em:	BioMed Central 2017

Osteoprotegerin and breast cancer risk by hormone receptor subtype: a nested case-control study in the EPIC cohort

Registros relacionados